Zai Lab (ZLAB) Projected to Post Quarterly Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Zai Lab to post earnings of ($0.38) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Zai Lab Trading Down 1.8%

Shares of Zai Lab stock opened at $19.37 on Wednesday. Zai Lab has a twelve month low of $15.96 and a twelve month high of $44.34. The stock has a market cap of $2.19 billion, a price-to-earnings ratio of -9.93 and a beta of 0.88. The company has a fifty day moving average price of $18.33 and a 200 day moving average price of $24.49.

Insider Activity

In related news, insider Rafael Amado sold 10,787 shares of the firm’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $17.43, for a total transaction of $188,017.41. Following the transaction, the insider directly owned 52,391 shares in the company, valued at $913,175.13. This trade represents a 17.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.96% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zai Lab stock. Royal Bank of Canada increased its position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 at the end of the most recent quarter. 41.65% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ZLAB shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a research report on Wednesday, January 21st. Jefferies Financial Group upgraded Zai Lab to a “strong-buy” rating in a report on Monday, January 19th. JPMorgan Chase & Co. lowered their target price on Zai Lab from $46.00 to $39.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Zacks Research lowered Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. Finally, UBS Group began coverage on Zai Lab in a research note on Wednesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $51.59.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.